Broader treatment coverage is part of the next editorial build.
Condition hub · vitiligo
Vitiligo: understand the condition and prepare your next conversation.
Use this hub to orient yourself, find the current phototherapy evidence, and see what SteadySkin is building next.
The most useful thing here
Walk in with the right questions.
Save the ones that fit. They remain in this browser until you clear them.
- What are we trying to change with this plan, and how will we decide whether it is helping?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which options should we compare before I make a decision?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What should I record between visits so you can see what actually happened?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Find the right depth
The treatment landscape.
No ranked ladder and no implied completeness. Each row says where the depth lives.
If phototherapy is on the table
The decision is only the beginning.
SteadySkin is building the practical path around the clinical conversation.
Sources
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022
British Journal of Dermatology (Goulden V, et al.)
Regulatory / guidelineIndependent
- Published
- 2022-09-01
- Last checked by us
- 2026-07-29
Read the sourceWhat this source does and does not support
Supports that therapeutic narrowband UVB lamps have an emission spectrum peaking near 311–313 nm, and that this narrow band was selected because it is the most effective part of the UVB spectrum for treating psoriasis. It is a clinical guideline for clinicians administering phototherapy; it does not establish any home-use dose, and this site never reproduces its dosing schedules.
Phototherapy — NB-UVB (patient information leaflet)
British Association of Dermatologists
Patient educationIndependent
- Published
- 2022-06-01
- Last checked by us
- 2026-07-29
Read the sourceWhat this source does and does not support
Supports, in plain patient-facing language, that narrowband UVB uses a small part of the UVB spectrum and is used for skin conditions including psoriasis, eczema and vitiligo. As patient-education material it is context, not primary evidence, for any efficacy claim. Its review date is June 2025, so re-verify before relying on it past then.
When you are ready to record
The app starts with vitiligo.
Everything on this website works without it.
Join the waitlist
One email when it is out. Nothing else, ever.